Seon-Cheol Park, Eun-Young Jang, Kiwon Kim, Hoseon Lee, Joonho Choi, Amitava Dan, A. Hussain, A. J. Tanra, Takahiro A. Kato, K. Chee, Sih-Ku Lin, Chay-Hoon Tan, A. Javed, N. Sartorius, N. Shinfuku, Y. Park
{"title":"在BPRS-6量表上建立精神分裂症严重程度范围的截止分数:来自REAP-AP的发现","authors":"Seon-Cheol Park, Eun-Young Jang, Kiwon Kim, Hoseon Lee, Joonho Choi, Amitava Dan, A. Hussain, A. J. Tanra, Takahiro A. Kato, K. Chee, Sih-Ku Lin, Chay-Hoon Tan, A. Javed, N. Sartorius, N. Shinfuku, Y. Park","doi":"10.1080/24750573.2019.1695994","DOIUrl":null,"url":null,"abstract":"ABSTRACT Objective: Using data from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP), our study aimed to establish the remission and severity ranges (mild, moderate, and severe) of schizophrenia on the Brief Psychiatric Rating Scale-6 (BPRS-6). Methods: A total of 1,438 patients with schizophrenia from India, Indonesia, Japan, Malaysia, and Taiwan were enrolled in the study. Using the receiver operating characteristic (ROC) curve analyses, the optimal cut-off scores for the remission and severity ranges on the BPRS-6 were established. Results: The scalability of the BPRS-6 was considered to have an acceptable “unidimensionality” (coefficient of scalability = 0.43). The cut-off scores for the remission of schizophrenia and mild, moderate, and severe schizophrenia can be optimally defined as the BPRS-6 total score of <5, 5–9, 10–19 and >20, respectively. Conclusion: The BPRS-6 can be a promising, brief, and unidimensional rating scale to supplement the measurement-based care of schizophrenia.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"14 1","pages":"895 - 898"},"PeriodicalIF":0.5000,"publicationDate":"2019-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Establishing the cut-off scores for the severity ranges of schizophrenia on the BPRS-6 scale: findings from the REAP-AP\",\"authors\":\"Seon-Cheol Park, Eun-Young Jang, Kiwon Kim, Hoseon Lee, Joonho Choi, Amitava Dan, A. Hussain, A. J. Tanra, Takahiro A. Kato, K. Chee, Sih-Ku Lin, Chay-Hoon Tan, A. Javed, N. Sartorius, N. Shinfuku, Y. Park\",\"doi\":\"10.1080/24750573.2019.1695994\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Objective: Using data from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP), our study aimed to establish the remission and severity ranges (mild, moderate, and severe) of schizophrenia on the Brief Psychiatric Rating Scale-6 (BPRS-6). Methods: A total of 1,438 patients with schizophrenia from India, Indonesia, Japan, Malaysia, and Taiwan were enrolled in the study. Using the receiver operating characteristic (ROC) curve analyses, the optimal cut-off scores for the remission and severity ranges on the BPRS-6 were established. Results: The scalability of the BPRS-6 was considered to have an acceptable “unidimensionality” (coefficient of scalability = 0.43). The cut-off scores for the remission of schizophrenia and mild, moderate, and severe schizophrenia can be optimally defined as the BPRS-6 total score of <5, 5–9, 10–19 and >20, respectively. Conclusion: The BPRS-6 can be a promising, brief, and unidimensional rating scale to supplement the measurement-based care of schizophrenia.\",\"PeriodicalId\":20847,\"journal\":{\"name\":\"Psychiatry and Clinical Psychopharmacology\",\"volume\":\"14 1\",\"pages\":\"895 - 898\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2019-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychiatry and Clinical Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/24750573.2019.1695994\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry and Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/24750573.2019.1695994","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Establishing the cut-off scores for the severity ranges of schizophrenia on the BPRS-6 scale: findings from the REAP-AP
ABSTRACT Objective: Using data from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP), our study aimed to establish the remission and severity ranges (mild, moderate, and severe) of schizophrenia on the Brief Psychiatric Rating Scale-6 (BPRS-6). Methods: A total of 1,438 patients with schizophrenia from India, Indonesia, Japan, Malaysia, and Taiwan were enrolled in the study. Using the receiver operating characteristic (ROC) curve analyses, the optimal cut-off scores for the remission and severity ranges on the BPRS-6 were established. Results: The scalability of the BPRS-6 was considered to have an acceptable “unidimensionality” (coefficient of scalability = 0.43). The cut-off scores for the remission of schizophrenia and mild, moderate, and severe schizophrenia can be optimally defined as the BPRS-6 total score of <5, 5–9, 10–19 and >20, respectively. Conclusion: The BPRS-6 can be a promising, brief, and unidimensional rating scale to supplement the measurement-based care of schizophrenia.
期刊介绍:
Psychiatry and Clinical Psychopharmacology aims to reach a national and international audience and will accept submissions from authors worldwide. It gives high priority to original studies of interest to clinicians and scientists in applied and basic neurosciences and related disciplines. Psychiatry and Clinical Psychopharmacology publishes high quality research targeted to specialists, residents and scientists in psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related sciences.